# US 2017/0281768 A1 · Novel nucleic acid molecules with antitumoral activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281768 A1
- Document ID: US20170281768A1
- Status: Published application
- Kind: A1
- Application number: 15/454,769
- Filed: 2017-03-09
- Published: 2017-10-05
- Earliest claimed: 2012-03-16
- Assignees: Covagen AG
- Applicants: Covagen AG
- Inventors: Simon Sebastian BRACK; Frédéric MOURLANE; Isabella TOLLER; Richard WOODS; Julian BERTSCHINGER; Dragan GRABULOVSKI; Babette SCHADE; Kristina KLUPSCH; Helen HACHEMI
- Web page: https://patentgrep.com/patent/US20170281768A1

## CPC

- C12N 9/12: transferring phosphorus containing groups, e.g. kinases (2.7)
- A01K 67/0278: Knock-in vertebrates, e.g. humanised vertebrates
- A61K 39/39591: {Stabilisation, fragmentation}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 16/30: from tumour cells
- C07K 16/32: against translation products of oncogenes
- A01K 2227/105: Murine
- A01K 2267/01: Animal expressing industrially exogenous proteins
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/77: Internalization into the cell
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K 2318/20: Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12Y 207/10002: Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

The present invention relates to a binding molecule that specifically binds to two different epitopes of an antigen expressed on tumor cells, wherein the binding molecule comprises: (a) a first binding (poly)peptide that specifically binds to a first epitope of said antigen expressed on tumor cells, wherein said first binding (poly)peptide is a Fyn SH3-derived polypeptide; and (b) a second binding (poly)peptide that specifically binds to a second epitope of said antigen expressed on tumor cells. The present invention further relates to a nucleic acid molecule encoding the binding molecule of the invention, a vector comprising said nucleic acid molecule as well as a host cell or a non-human host transformed with said vector. The invention further relates to a method of producing a binding molecule of the invention as well as to pharmaceutical and diagnostic composition. Moreover, the present invention also relates to the binding molecule, the nucleic acid molecule, the vector or the host cell of the invention for use in the treatment of tumors.

## Claims

### Claim 1

A binding molecule that specifically binds to two different epitopes of an antigen expressed on tumor cells said molecule comprising:
(a) a first binding (poly)peptide that specifically binds to a first epitope of said antigen expressed on tumor cells, wherein said first binding (poly)peptide is a Fyn SH3-derived polypeptide; and
(b) a second binding (poly)peptide that specifically binds to a second epitope of said antigen expressed on tumor cells.

### Claim 2 (depends on 1)

The binding molecule of claim 1, wherein the antigen expressed on tumor cells is HER2, HER1, HER3, HER4, receptors of the insulin, PDGF, FGF, VEGF, HGF, Trk, Eph, AXL, LTK, TIE, ROR, RET, KLG, RYK, MuSK families, EpCAM, CD20, CD33, CD52, or CD30.

### Claim 3 (depends on 1)

The binding molecule of claim 1, wherein the second binding (poly)peptide is an antibody.

### Claim 4 (depends on 1)

The binding molecule to of claim 1, wherein the first and second binding (poly)peptide are linked by a linker.

### Claim 5 (depends on 4)

The binding molecule to of claim 4, wherein the linker is a peptide-linker.

### Claim 6 (depends on 1)

The binding molecule of claim 1, wherein said binding molecule further comprises at least one additional (poly)peptide.

### Claim 7 (depends on 1)

The binding molecule of claim 1, wherein the first binding (poly)peptide comprises or consists of
(i) an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to 152; or
(ii) an amino acid sequence having at least 65% sequence identity to the amino acid sequence of SEQ ID NO: 1.

### Claim 8 (depends on 1)

The binding molecule of claim 1, wherein the second binding (poly)peptide is an antibody, wherein
(a) the heavy chain of the antibody comprises or consists of the amino acid sequence of SEQ ID NO: 154 and the light chain of the antibody comprises or consists of the amino acid sequence of SEQ ID NO: 155;
(b) the heavy chain of the antibody comprises or consists of SEQ ID NO: 160 and the light chain of the antibody comprises or consists of the amino acid sequence of SEQ ID NO: 163;
(c) the heavy chain of the antibody comprises or consists of an amino acid sequence having at least 65% sequence identity to the amino acid sequence of SEQ ID NO: 154 and the light chain of the antibody comprises or consists of an amino acid sequence having at least 65% sequence identity to the amino acid sequence of SEQ ID NO: 155; or
(d) the heavy chain of the antibody comprises or consists of an amino acid sequence having at least 65% sequence identity to the amino acid sequence of SEQ ID NO: 160 and the light chain of the antibody comprises or consists of an amino acid sequence having at least 65% sequence identity to the amino acid sequence of SEQ ID NO: 163.

### Claim 9 (depends on 1)

A nucleic acid molecule encoding the binding molecule of claim 1.

### Claim 10 (depends on 9)

A vector comprising the nucleic acid molecule of claim 9.

### Claim 11 (depends on 10)

A host cell or a non-human host transformed with the vector of claim 10.

### Claim 12 (depends on 11)

A method for the production of a binding molecule that specifically binds to two different epitopes of an antigen expressed on tumor cells comprising culture of the host cell of claim 11 under suitable conditions and isolation of the binding molecule produced.

### Claim at position 13

13-15. (canceled)

### Claim 16 (depends on 1)

A method for treating a tumor comprising administering a composition comprising the binding molecule of claim 1.

### Claim 17 (depends on 16)

The method of claim 16, wherein the tumor is a breast cancer, ovarian cancer, bladder cancer, salivary gland cancer, endometrium cancer, pancreatic cancer, thyroid cancer, kidney cancer, lung cancer, cancer concerning the upper gastrointestinal tract, colon cancer, colorectal cancer, prostate cancer, squamous-cell carcinoma of the head and neck, cervical cancer, glioblastoma, malignant ascites, lymphoma, or leukemia tumor.

### Claim 18 (depends on 9)

A method for treating a tumor comprising administering a composition comprising the nucleic acid of claim 9.

### Claim 19 (depends on 18)

The method of claim 18, wherein the tumor is a breast cancer, ovarian cancer, bladder cancer, salivary gland cancer, endometrium cancer, pancreatic cancer, thyroid cancer, kidney cancer, lung cancer, cancer concerning the upper gastrointestinal tract, colon cancer, colorectal cancer, prostate cancer, squamous-cell carcinoma of the head and neck, cervical cancer, glioblastoma, malignant ascites, lymphoma, or leukemia tumor.

### Claim 20 (depends on 10)

A method for treating a tumor comprising administering a composition comprising the vector of claim 10.

### Claim 21 (depends on 20)

The method of claim 20, wherein the tumor is a breast cancer, ovarian cancer, bladder cancer, salivary gland cancer, endometrium cancer, pancreatic cancer, thyroid cancer, kidney cancer, lung cancer, cancer concerning the upper gastrointestinal tract, colon cancer, colorectal cancer, prostate cancer, squamous-cell carcinoma of the head and neck, cervical cancer, glioblastoma, malignant ascites, lymphoma, or leukemia tumor.

### Claim 22 (depends on 11)

A method for treating a tumor comprising administering a composition comprising the host cell of claim 11.

### Claim 23 (depends on 22)

The method of claim 22, wherein the tumor is a breast cancer, ovarian cancer, bladder cancer, salivary gland cancer, endometrium cancer, pancreatic cancer, thyroid cancer, kidney cancer, lung cancer, cancer concerning the upper gastrointestinal tract, colon cancer, colorectal cancer, prostate cancer, squamous-cell carcinoma of the head and neck, cervical cancer, glioblastoma, malignant ascites, lymphoma, or leukemia tumor.
